Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azathioprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | HBB | P68871 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | TP53 | P04637 | 2/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azathioprine SCHEMBL26152 | 1.00 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4278 | 0.99 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4436347 | 0.99 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL29693611 | 0.99 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL3089846 | 0.98 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL502599 | 0.98 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4259183 | 0.91 | MAPT (0.84) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8354969 | 0.90 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8511946 | 0.90 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL2328735 | 0.90 | MAPT (0.82) | MAPTHBBLMNATP53GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12178834-B2 | Treating myelin diseases with optimized cell preparations | UNIVERSITY OF ROCHESTER (US) | 2024-12-31 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-11596700-B2 | Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder | UNIVERSITY OF ROCHESTER (US) | 2023-03-07 | — | — | US | claimed |
| US-20220273728-A1 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS | UNIV ROCHESTER (US) | 2022-09-01 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-7901453-B2 | Coated implantable medical device | COOK INCORPORATED (US) | 2011-03-08 | — | — | US | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080145399-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | COOK MEDICAL TECHNOLOGIES LLC | 2008-06-19 | — | — | US | claimed |
| US-20080145398-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20030036794-A1 | Coated implantable medical device | COOK INCORPORATED | 2003-02-20 | — | — | US | claimed |
| CN-116406355-B | P38 alpha mitogen-activated protein kinase inhibitors | GEN1E生命科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | TRIS PHARMA, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-0055113-A2 | Deca- undeca- dodeca- and tridecapeptides with thymic activity, method for their preparation and compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1982-06-30 | — | — | EP | disclosed |
| US-4046877-A | HUMAN SERUM PREALBUMIN | SYNTEX (U.S.A.) INC. (US) | 1977-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605333-B2 | Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release | SI, GRPR, FABP2 | MAPT 483/4885HBB 115/4885LMNA 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.